Analyst Group Comments on Nosa Plugs’ Q2 Report
Nosa Plugs AB (“Nosa Plugs” or “the Company”) published its interim report for the second quarter of 2025 on August 22, 2025.
Below are some highlights we have chosen to emphasize from the report:
- Record revenues
- Continued strong gross margin
- Strong cost control contributing to improved results – profitability expected in Q4-25
- Positive study results regarding Nosa Drug Delivery
- Conditional agreement to acquire Pharmacure and completion of a directed share issue
In conclusion, Analyst Group views the Q2-25 report as stable, showing strong growth and improvements in both gross and EBITDA margin. While Q3-25 will be a tough comparison quarter due to the 124% growth achieved in Q3-24 from the successful rollout of Smell Training, we expect that the consolidation of Pharmacure will generate synergies driving both growth and profitability. Meanwhile, the existing product portfolio continues to expand and generate organic growth.
Read Analyst Group’s comment on the report here
About Analyst Group: One of the Nordic’s leading analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of an equity research report on Nosa Plugs. Readers may assume that Analyst Group has received compensation for making the equity research report. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.